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Comprehensive characterization of human tissues promises novel insights into the biological
architecture of human diseases and traits. We assessed metabonomic, transcriptomic, and genomic
variation for a large population-based cohort from the capital region of Finland. Network analyses
identified a set of highly correlated genes, the lipid–leukocyte (LL) module, as having a prominent
role in over 80 serum metabolites (of 134 measures quantified), including lipoprotein subclasses,
lipids, and amino acids. Concurrent association with immune response markers suggested the LL
module as a possible link between inflammation, metabolism, and adiposity. Further, genomic
variation was used to generate a directed network and infer LL module’s largely reactive nature to
metabolites. Finally, gene co-expression in circulating leukocytes was shown to be dependent on
serum metabolite concentrations, providing evidence for the hypothesis that the coherence of
molecular networks themselves is conditional on environmental factors. These findings show the
importance and opportunity of systematicmolecular investigation of human population samples. To
facilitate and encourage this investigation, the metabonomic, transcriptomic, and genomic data
used in this study have been made available as a resource for the research community.
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Introduction
Our understanding of the genetic basis of complex disease has
recently been transformed by genome-wide association
studies, leading to the identification and cataloging of
hundreds of genomic loci associated with human disease
(Hindorff et al, 2009). In parallel, current technologies have
brought systematic functional investigation of the underlying
disease pathways within reach. Building upon previous work
to integrate genetic and transcriptional profiles to uncover
disease genes (Hubner et al, 2005; Mehrabian et al, 2005),
Chen et al (2008) and Emilsson et al (2008) constitute two
recent large-scale studies, which led to the identification of
novel candidate genes for obesity and the characterization of
the macrophage-enriched metabolic network module, a
subnetwork enriched for genes in inflammatory processes
and metabolic syndrome. These studies added to the growing
body of evidence linking inflammation and the immune
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response with systemic metabolism and metabolic disorders
(Hotamisligil, 2006).
We recently characterized the lipid–leukocyte (LL) module,
a cluster of tightly correlated co-expressing genes, that
harbored key basophil and mast cell (BMC)-specific mediators
of the immune response and strongly associated with total
measures of serum triglycerides (TGs), high-density lipopro-
tein (HDL) cholesterol (C), and apolipoprotein B (APOB)
(Inouye et al, 2010). However, lipid metabolism is hetero-
geneous and lipoprotein subpopulations are presently utilized
to both appreciate the various counteracting metabolic
phenomena and more accurately assess the risk for various
vascular outcomes (Chasman et al, 2009). Further, lipids
comprise only a fraction of the metabolic compounds in the
circulatory system; therefore, a comprehensive assessment is
essential to understand potentially causative and reactive
relationships between serum metabolites and molecular net-
works (Holmes et al, 2008). To this end, the serum
metabonomes of 518 individuals from a population-based
cohort, the Dietary, Lifestyle, and Genetic determinants of
Obesity and Metabolic syndrome (DILGOM) study, were
determined by proton nuclear magnetic resonance spectro-
scopy (NMR). The DILGOM study consists of unrelated
individuals, 240 males and 278 females, aged 25–74 years,
sampled from the capital region of Finland (Supplementary
Figure 1). Combined with the genome-wide profiles of genetic
and transcriptional variation from blood leukocytes of the
same individuals, this information represents a powerful
resource for large-scale functional investigation, thus we have
made the data publically available for researchers (see Data
Availability section of Materials and methods). In this study,
we provide both a proof of concept and roadmap for integrated
analysis of variation at the genetic, transcriptional, and
metabonomic levels. In doing so, we also comprehensively
characterize the role of LL module as a network linking
metabolic compounds and the immune response.
Results and Discussion
Blood serum is a site of systemic metabolism in the human
body. However, the vast array of molecular compounds in
serum makes their identification and quantification a challen-
ging task. Here, we partitioned serum compounds into three
molecular windows using a unique NMR metabonomics
platform (Soininen et al, 2009) with an optimized measure-
ment and analysis protocol providing absolute quantitative
information on 134 metabolic measures, including 14
lipoprotein subclasses (see Materials and methods and
Supplementary Figure 2), various low-molecular-weight me-
tabolites, and also individual lipid molecules together with
their degree of (poly)(un)saturation (Supplementary Table 1).
An overview of the data integration and the different
analysis in the study is given in Figure 1.
A gene network associated with blood metabolites
Across all metabolites, 1341 significant gene expression
associations were observed; however, the degree of inter-
correlation between metabolites was strong (Supplementary
Figure 3). Genes belonging to the core LL module (HDC,
FCER1A, GATA2, CPA3, MS4A2, SPRYD5, and SLC45A3) were
not only strongly associated with lipoprotein and lipid levels
but were also among the strongest signals for glycoproteins,
isoleucine, and 3-hydroxybutyrate. Glycoproteins are known
to have potentially allergenic effects (Altmann, 2007); how-
ever, the associations with isoleucine (an essential amino acid)
and creatine (a nitrogenous organic acid) suggest LL module’s
involvement in pathways outside of lipid metabolism and a
potential molecular clue as to how BMC-mediated inflamma-
tion may arise from various serum compounds.
Network analysis of gene co-expression showed the
clustering of LL module genes (Supplementary Table 2) and
the association of the core module genes with metabolites
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Figure 1 Overview of data integration and analyses. A high-level view of the study design and analysis employed.
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(Supplementary Figure 6) (Horvath and Dong, 2008; Lang-
felder and Horvath, 2008). A Spearman’s rank correlation of
the LL module expression profile (first principal component)
with metabolite distributions offered fine-scale detail of
potentially causative/reactive effects (Table I, see Supplemen-
tary Figures 7–16). After correction for the 21 modules tested
(a Bonferroni-corrected significance level of 2.4103),
expression of LL module was, as expected from univariate
analysis, positively associated with glycoprotein
(P¼1.83108) and creatine levels (P¼9.02104), and
negatively associated with isoleucine (P¼4.031016). Our
previous findings showed association of LLmodule expression
with total HDL and APOB but not with total low-density
lipoprotein (LDL) (Inouye et al, 2010). The deeper lipoprotein
phenotypes obtained by serum NMR metabonomics allowed
for division of the APOB–lipoprotein cascade into 10 sub-
classes: six for the very-low-density lipoprotein (VLDL)
fraction, the intermediate-density lipoprotein (IDL), and
three LDL subclasses. All VLDL subclasses had a strong
correlation with LL module expression, indicating dominance
of the VLDL fraction in the APOB association (Table I), as could
be expected (Lusis et al, 2008). The current results further
validated that, at current detection power, there remained little
evidence for association with total LDL-C (P¼0.07), while a
fewmeasures related to the medium and small LDL subclasses
did associate weakly with LL module expression (Supple-
mentary Figure 14).
Of particular interest were the opposite metabolic correla-
tions observed for HDL subclasses both in terms of LL module
association and overall (Supplementary Figure 3). For
example, the smallest HDL subclass behaved similarly to the
VLDL subclasses and had a negative correlationwith the larger
HDL subclasses. This finding has also been observed by others
(Chasman et al, 2009) and suggests that the serum HDL
fraction does not have a coherent physiological function and
Table I Significant LL module associations with serum metabolite concentra-
tions and immune response markers
Spearman’s
correlation
P-value
Metabolite
Concentration of chylomicrons and
extremely large VLDL particles
0.464 4.46E29
Triglycerides in medium VLDL 0.442 3.46E26
Concentration of large VLDL particles 0.441 4.51E26
Free cholesterol in large VLDL 0.441 4.89E26
Triglycerides in large VLDL 0.441 5.20E26
Triglycerides in VLDL 0.439 7.25E26
Concentration of very large VLDL particles 0.439 8.88E26
Total cholesterol in large VLDL 0.438 1.00E25
Triglycerides in very large VLDL 0.438 1.09E25
Phospholipids in large VLDL 0.437 1.43E25
Total lipids in large VLDL 0.436 1.98E25
Triglycerides in VLDL (Lipido) 0.434 3.77E25
Concentration of medium VLDL particles 0.43 8.80E25
Cholesterol esters in large VLDL 0.43 9.68E25
Total lipids in very large VLDL 0.429 1.32E24
Total lipids in medium VLDL 0.428 1.59E24
Serum total triglycerides 0.427 2.53E24
Phospholipids in medium VLDL 0.423 6.17E24
Triglycerides in small VLDL 0.421 1.27E23
Total triglycerides 0.418 2.87E23
Mobile lipids CH2 0.417 3.25E23
Free cholesterol in medium VLDL 0.417 3.26E23
Phospholipids in very large VLDL 0.414 6.36E23
Table I Continued
Spearman’s
correlation
P-value
Ratio of triglycerides to phosphoglycerides 0.41 2.14E22
Total cholesterol in medium VLDL 0.405 7.78E22
Concentration of small VLDL particles 0.394 1.18E20
Cholesterol esters in medium VLDL 0.383 1.36E19
Phospholipids in chylomicrons
and extremely large VLDL
0.381 2.56E19
Total lipids in chylomicrons and
extremely large VLDL
0.376 7.91E19
Triglycerides in small HDL 0.375 1.00E18
Total lipids in small VLDL 0.374 1.18E18
Triglycerides in chylomicrons and
extremely large VLDL
0.372 2.03E18
Phospholipids in small VLDL 0.362 1.70E17
Mobile lipids CH3 0.35 2.11E16
Isoleucine 0.347 4.03E16
Unsaturated lipids 0.343 9.41E16
Free cholesterol in small VLDL 0.341 1.43E15
Triglycerides in very small VLDL 0.337 2.97E15
o-9 and saturated fatty acids 0.329 1.61E14
Total fatty acids 0.316 1.66E13
Total cholesterol in IDL (Lipido) 0.307 9.13E13
Apolipoprotein B by apolipoprotein A-I 0.299 3.90E12
Total cholesterol in small VLDL 0.278 1.18E10
Free cholesterol in large HDL 0.273 2.59E10
o-6 and -7 fatty acids 0.269 5.02E10
Apolipoprotein B 0.263 1.17E09
Average number of methylene groups
per a double bond
0.263 1.24E09
Ratio of bisallylic groups to total fatty acids 0.263 1.29E09
Ratio of bisallylic groups to double bonds 0.255 4.16E09
Total cholesterol in large HDL 0.253 5.15E09
Total lipids in large HDL 0.245 1.57E08
Phospholipids in large HDL 0.244 1.77E08
Glycoproteins 0.244 1.83E08
Cholesterol esters in large HDL 0.243 2.26E08
Concentration of large HDL particles 0.241 2.87E08
Average number of double bonds in
a fatty acid chain
0.24 3.39E08
Leucine 0.236 5.58E08
Total cholesterol in HDL2 (Lipido) 0.235 5.94E08
Ratio of o-9 and saturated fatty acids
to total fatty acids
0.234 6.82E08
Phospholipids in very large HDL 0.221 4.00E07
Total cholesterol in HDL3 (Lipido) 0.211 1.30E06
Concentration of very large HDL particles 0.205 2.56E06
Triglycerides in IDL 0.199 5.24E06
Total lipids in very large HDL 0.198 5.49E06
Ratio of o-6 and -7 fatty acids to total
fatty acids
0.194 8.94E06
Total cholesterol in HDL 0.191 1.17E05
Free cholesterol in very large HDL 0.186 1.96E05
Concentration of very small VLDL particles 0.182 3.23E05
Cholesterol esters in very large HDL 0.177 5.08E05
3-Hydroxybutyrate 0.171 9.48E05
Concentration of small LDL particles 0.17 1.02E04
Total cholesterol in very large HDL 0.168 1.25E04
18:2, Linoleic acid 0.154 4.48E04
Concentration of small HDL particles 0.154 4.48E04
Total phosphoglycerides 0.151 5.78E04
Total lipids in small LDL 0.147 7.87E04
Other polyunsaturated fatty acids than 18:2 0.146 8.30E04
Creatine 0.145 9.02E04
Total lipids in very small VLDL 0.145 9.13E04
Description of average fatty acid chain
length (not carbon number)
0.141 1.26E03
Phospholipids in medium LDL 0.141 1.31E03
Triglycerides in very large HDL 0.141 1.33E03
Immune response marker
Interleukin-1 receptor antagonist 0.203 3.14E06
High-molecular-weight adiponectin 0.189 1.55E05
C-reactive protein 0.16 2.62E04
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that the smallest HDL particles are a metabolically distinct
entity, tightly positively connected with TG metabolism and
the APOB lipoprotein cascade. Thereby, the smallest HDL
particles appear potentially proatherogenic in contradiction to
the larger particles thought to have a role in the reverse C
transport (Tall, 1998). The capacity of total HDL-C measure-
ment to describe the functional aspects of HDL metabolism is
dependent on the relative concentrations of circulating HDL
subclasses; the more large particles the better the measure will
be, but if there is a preponderance of smaller HDL particles, its
physiological meaning is confounded. The size-dependent
metabolic behavior of HDL particles clearly represents the
inadequacy of current total lipoprotein measures used in
clinical practice but also offers an opportunity to delve more
deeply into the (patho)physiology of lipoprotein metabolism
and the immune response.
The LL module is associated with interleukin-1
receptor antagonist, high-molecular-weight
adiponectin, and C-reactive protein
Given the gene composition of LL module, serum markers of
the immune response were measured for all individuals in the
DILGOM study. These included total serum immunoglobulin E
(IgE), interleukin-1 receptor antagonist (IL-1ra), C-reactive
protein (CRP), and high-molecular-weight adiponectin
(HMWA). As with blood metabolites, the expression of LL
module was tested against these new variables (Table I). LL
module exhibited strong negative association with IL-1ra and
CRP levels (P¼3.1106 and 2.6104, respectively) and
strong positive association with HMWA levels (P¼1.6105).
Total serum IgE levels did not show significant association
with LL module (P¼0.60) nor with FCER1A expression itself
(P¼0.42), findings which were consistent with previous
observations (Weidinger et al, 2008).
Associations with IL-1ra, CRP, and HMWA represent intri-
guing insights into LLmodule’s potential physiological role. The
IL-1 system is important in insulin resistance, glucose home-
ostasis, and inflammation. IL-1ra is a cytokine, which inhibits
the activation of IL-1 receptor, in turn dampening the
inflammatory response. The modulation of IL-1ra is a compen-
satory phenomenon to the levels of proinflammatory IL-1b;
however, recombinant human IL-1ra has shown promise as a
treatment for type 2 diabetes (Larsen et al, 2007). Interestingly,
IL-1b has also been shown to induce degranulation ofmast cells
(Haak-Frendscho et al, 1988). Adiponectin is a hormone
secreted by adipocytes. It is inversely related to incidence of
obesity and diabetes andwas recently shown to be the strongest
protective factor in a set of novel biomarkers for type 2 diabetes
(Salomaa et al, 2010). However, its association with cardiovas-
cular disease is controversial (Sattar et al, 2008). CRP is an acute
phase reactant and inflammatory marker. It has been shown to
be induced by IL-1 (Ganapathi et al, 1991) and inhibited by
adiponectin (Devaraj et al, 2008).
A directed network of blood metabolites and the
LL module
While we have considered undirected network models for the
association of LL module expression with metabolite concen-
trations, the use of genetic variants allows for the construction
of an edge-oriented network to infer gene/gene or gene/me-
tabolite causality (Schadt et al, 2005; Li et al, 2006; Aten et al,
2008). Using Network Edge Orientation (NEO) conditional
correlation analysis (Aten et al, 2008), we inferred an edge-
oriented network of core LL module gene expression with all
metabolites that (a) were significantly associated with LL
module expression and (b) displayed the genetic component
needed for edge orientation (at least one SNP associated with
Po5.0107). This led to a network with 36 nodes (the 7 core
LL genes plus 29 metabolites) and 137 causal edges (Figure 2
and Supplementary Table 3). Core LL module was largely
reactive to fatty acids and high/low/intermediate-density
lipoprotein fractions; however, some lipoprotein components
(notably the free C and phospholipids in large VLDL) contra-
dicted this trend and appeared to be driven by expression of
HDC, SPRYD5, and CPA3. Interestingly, the TGs present in the
smallest HDL particles (those which showed the strongest
negative relationship with larger HDL subclasses, see Supple-
mentary Figure 3) were strongly driven by the concentration of
large/medium HDL.
Conditional co-expression: dependency on
metabolite environment
The large number of unrelated individuals in the data set
allowed for the investigation of the metabolite dependencies
underlying the co-expression in LL module. For example, if
module co-expression is reduced in the face of extreme
metabolite levels, then this offers potential biological insight
into how cells might regulate gene expressionwhen faced with
different extracellular environments. For each metabolite the
log2-normalized expression values were partitioned into
quintiles of metabolite level, and the co-expression of all core
LL module gene pairs were measured via a Spearman’s rank
correlation coefficient. A linear model was fitted to all co-
expression pairs across the quintiles in order to identify trends in
co-expression. We refer to this fitted model as co-expression
trend. If there is no co-expression trend, then the slope of the
fitted line should be zero (or not significant). In our data, there
were 63metabolites, which showed both a significant association
(Po2.4103) with LL module expression and a significant co-
expression trend (Po0.05). For all of thesemetabolites, therewas
an inverse relationship between the direction of association with
LL module expression and the direction of co-expression trend
(Figure 3). To put it in another way, if both LLmodule expression
and metabolite levels increase (as is the case with HDL-C), then
the connectivity of the core genes in LL module will decrease.
This raises the hypothesis that the functionality of LL module is
reduced at increasing level of metabolites, such as large/medium
HDL and 3-hydroxybutyrate, and increased by metabolites such
as TGs, glycoproteins, and small HDL. As the LLmodule contains
key genes specific to mast cells and basophils, this represents an
intriguing prediction as to how a gene network in these cells
might respond to extracellular metabolites.
Conclusions
As the quantification of human tissues acquires more
dimensions, our understanding of gene function and interaction
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will become immensely enriched. In this report, we provide a
proof of concept for the integration of metabonomic, transcrip-
tomic, and genomic data. In doing so, we elucidate functional
aspects of LL module within and outside lipid pathways
by showing its strong correlations with lipoprotein particle
size, organic acids, and immune responsemarkers.We also show
the dependency of the network connections on the concentra-
tions of circulating metabolites. Building upon our knowledge of
genetic variation associated with lipid levels, we construct an
edge-oriented graph to infer causality, providing population-
based evidence that LL module is reactive to both HDL and
small VLDL subclasses and that components of the smallest
HDL subclasses are negatively correlated and reactive to larger
HDL subclasses.
From our systems analysis of a population-based cohort, we
have shown that LL module implicates mast cells and
basophils as having a key role in systemic metabolism. This
study dramatically increases LL module’s blood metabolite
associations to 83 from 3 (Inouye et al, 2010) and, through the
gene content of LL module, offers a firm basis for biochemical
studies targeting metabolite-stimulated mast cell and basophil
secretion of histamine and proteases, which can in turn act on
many tissues including vasculature and inflammatory.
Further, associations with IL-1ra, HMWA, and CRP represent
potentially fruitful research avenues in the connection of
adiposity, inflammation and, through lipoproteins, atherogen-
esis (Lyon et al, 2003).
Taken together, these observations offer a comprehensive
viewof interactions between an immune response subnetwork
and serum metabolic compounds and the inadequacy of
current total cholesterol measures. This novel combination of
metabonomic, transcriptomic, and genomic profiling illus-
trates the immense potential for integrative genomics in
epidemiology.
Materials and methods
Sample collection, genotyping, and expression
Samples were collected as part of the Dietary, Lifestyle, and Genetic
determinants of Obesity and Metabolic syndrome (DILGOM) study.
Study participants were aged 25–74 years and were drawn from the
Helsinki/Vantaa area of southern Finland. Participants were asked to
fast overnight for a period of at least 10 h before giving a blood sample.
Blood samples were left at room temperature for 45min before the
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Figure 2 Edge-directed network of LL module and serum metabolites. Genetic variation was used to infer a causal network of core LL module expression and
metabolites (see Supplementary Methods and Supplementary Table 1 for abbreviations). Core LL module genes are represented by purple nodes in the upper left,
whereas metabolites significantly associated with genetic variation and LL module are denoted by all other nodes. Arrows denote directed edges. (A) Shows core LL
module (red) reactivity to most lipoprotein subclass levels (green); however, two components of large VLDL (blue) were predicted downstream of CPA3, SPRYD5, and
HDC expression. (B) Shows that triglycerides in the small HDL subclass (red) are predicted to be largely reactive to concentrations of the larger HDL subclasses (green).
Source data is available for this figure at www.nature.com/msb.
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serum and plasma were separated via centrifugation and subsequent
storage in a 701C freezer.
Extraction, purification, and quantification of DNAwere performed
as previously described (Inouye et al, 2010) before genotyping on the
Illumina 610-Quad SNParray (Illumina Inc., SanDiego, CA, USA). RNA
protocols for the Illumina HT-12 expression array were also previously
described (Inouye et al, 2010). Technical replicates for each sample
were done.
Serum NMR metabonomics
We have recently introduced a high-throughput serum NMR metabo-
nomics platform with an optimized measurement and analysis
protocol, providing absolute quantitative information on B140
metabolic measures (Ala-Korpela et al, 2009; Mora et al, 2009;
Soininen et al, 2009). The methodology is based on three molecular
windows, two of which (LIPO and low-molecular-weight molecule
(LMWM)) are applied to native serum and one for serum lipid extracts
(LIPID). The LIPO window gives information, e.g., on the lipoprotein
subclass distribution and lipoprotein particle concentrations for 14
lipoprotein subclasses, and the LMWM window on various low-
molecular-weight metabolites such as amino acids, 3-hydroxybuty-
rate, and creatinine. The combination of these twomolecular windows
is likely to contain most of the metabolic information available by 1H
NMR metabonomics of native serum (Ala-Korpela, 1995, 2008). The
LIPID window is run from serum lipid extracts to obtain detailed
molecular information on various serum lipid constituents, such as
free and esterified C, sphingomyelin, (poly)(un)saturation and o-3
fatty acids (Tukiainen et al, 2008).
In our setup, the NMR data are measured using a Bruker AVANCE III
spectrometer operating at 500.36MHz (1H observation frequency;
11.74T) and equipped with an inverse selective SEI probehead,
including an automatic tuning and matching unit and a z-axis gradient
coil for automated shimming. A BTO-2000 thermocouple serves to
temperature stabilization, the sample at the level of approximately
0.011C. Notably, very stable and high-performance electronics is also a
prerequisite for some of the implemented concepts, including
metabolite quantification without per sample chemical referencing
or double tube systems (Soininen et al, 2009).
The serum samples are stored in a freezer at 801C. Before sample
preparation, the frozen samples are first slowly thawed in a refrigerator
(þ 41C) overnight. The samples are then mixed gently and spun in a
centrifuge at 3400 g to remove possible precipitate. Aliquots of each
sample (300 ml) are mixed with 300ml of sodium phosphate buffer
(75mM Na2HPO4 in 80%/20% H2O/D2O, pH 7.4; including also
0.08% sodium trimethylsilyl [2,2,3,3-D4]propionate and 6.2mM
sodium azide). The sample preparation is done automatically with a
Gilson Liquid Handler 215 to 5-mm-outer-diameter standard NMR
tubes. In the automatic preparation procedure, 300ml of buffer is first
transferred into the NMR tubes, after which 300ml of serum is added to
the buffer and the resulting solution is mixed thoroughly by aspirating
three times.
The LIPO window represents a conventional spectrum of human
serum showing broad overlapping resonances arising mainly from
different lipidmolecules in various lipoprotein particles. The LIPO data
are now recorded with 80 k data points after four dummy scans using
eight transients acquired with an automatically calibrated 901 pulse
and applying a Bruker noesypresat pulse sequencewithmixing time of
10ms and irradiation field of 25Hz to suppress the water peak. The
acquisition time is 2.7 s and the relaxation delay 3.0 s. The 901 pulse is
calibrated automatically for each sample. A constant receiver gain
setting is used for all the samples.
Figure 3 Conditional co-expression of LL module. Core LL module expression was partitioned into quintiles based on metabolite concentration rank. For each quintile
(x axis, lowest to highest metabolite concentration), co-expression of all non-redundant pairs was calculated using Spearman’s rank correlation coefficient (y axis). Fitting
a linear model to all co-expression pairs suggests that if LL module expression is negatively correlated with metabolite concentration, then co-expression among genes
belonging to LL module increases and vice versa.
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The LMWM spectrum is dominated by numerous glucose reso-
nances and shows signals from various LMWMs. In addition, some
lipid resonances are still visible in the LMWM spectrum, representing
the most mobile CH3 and (CH2)n groups of lipid molecules in the
lipoprotein particles. The LMWM data are acquired with such
spectrometer settings (using a T2-relaxation-filtered pulse sequence)
that suppress most of the broad macromolecule and lipoprotein lipid
signals and in that way enhance the detection of rapidly tumbling
smaller solutes, i.e., with 64 k data points using 24 transients acquired
after four steady-state scans with a Bruker 1D CPMG pulse sequence
with water peak suppression and a 78ms T2-filter with a fixed echo
delay of 403 ms to minimize diffusion and J-modulation effects. The
acquisition time is 3.3 s and the relaxation delay 3.0 s. Both LIPO and
LMWM data are processed and phase corrected in an automated
manner. Before Fourier transformations to spectra, the FIDs (both LIPO
and LMWM) are zero-filled to 128 k data points and then multiplied
with an exponential window function with a 1.0Hz line broadening.
Serum lipid extraction is carried out by adding 5ml of methanol,
10ml dichloromethane, and 15ml 0.15M sodium chloride solution to
the serum samples (including 300ml of serum and 300 ml of the NMR
buffer). The samples are shaken and centrifuged at 2400 g for 20min
at 41C. The organic phase is recovered and the aqueous phase is then
extracted again with 10ml of dichloromethane to enhance the yield.
After shaking and centrifuging (as before), the organic phase is
recovered. The separated organic phases are combined and evaporated
to dryness with pressurized air. For the NMR measurements, the lipid
extracts are dissolved into 0.6ml of CDCl3 containing 0.03% of
tetramethylsilane to serve as a chemical shift reference. The 64 k LIPID
data are acquired using 32 transients after four dummy scans. A
relaxation delay of 3.0 s and an acquisition time of 3.3 s are used. The
measured data are zero-filled to 128 k and multiplied with an
exponential window function with a line broadening of 0.5Hz.
1H NMR is inherently a quantitative technique allowing for absolute
metabolite quantification. Although the multi-metabolic nature of
serum inevitably causes signal overlap, the metabolite content and
concentrations can be extracted by appropriate experimental settings
and advanced computational techniques (Ala-Korpela, 1995). In the
case of the heavily overlapping data of lipoprotein lipids in the LIPO
window, it is our experience that regression modeling performs more
reliably than line fitting-based approaches. Therefore, we have now
implemented several lipoprotein subclasses (e.g., VLDL subclasses),
as well as other lipoprotein (e.g., HDL-C), and serum lipid (e.g., TGs)
quantificationmodels using regressionmodeling. Thesemodels can be
directly applied to the LIPO spectra in an automated manner and the
computation of the measures is instant (as the analysis with existing
models is non-iterative). A simplified and computationally more
efficient modification of the approach presented recently in Vehtari
et al (2007) is used. All the models used are cross-validated against
NMR-independent lipid data. Before applying the predictive models,
we verify that the new input spectrum lies within the limits (±10%) of
the training data set; otherwise, the particular sample is rejected from
the subclass analyses with no outcome.
The method of choice to quantify the low-molecular-weight
metabolites (as well as the residual lipoprotein lipids resonances) in
the LMWMspectra and the lipid signals in the LIPID spectra is iterative
lineshape fitting analysis. A simple singlet-multiplet approach works
well for the majority of the low-molecular-weight metabolites. A
model lineshape-based approach needs to be adopted in the case of the
LIPID spectra to enable quantitative analysis of severely overlapping
peaks and to increase the quantification accuracy (Mierisova and Ala-
Korpela, 2001). Intensity ratios of well-defined multiplets are used as
constraints, and, in some cases, the known coupling constants or
relative line widths are also constrained. A number of constraints were
created based on model spectra that were acquired from pure lipid
compounds. This kind of analysis is often termed as ‘the use of
biochemical prior knowledge’ and its use is recommended to decrease
the mathematical uncertainties with overlapping resonances
(Mierisova and Ala-Korpela, 2001). This sophisticated methodology
allows us to get information on the amounts of several lipid
components, e.g., sphingomyelin ando-3 fatty acids. Also, the average
degree of (poly)(un)saturation can be calculated from these variables.
Absolute quantification cannot be directly established in the lipid
extraction procedure due to some experimental variation in the lipid
acquisition. Therefore, each LIPID spectrum is scaled (via the fitted C
resonances) according to the serum total C as estimated from the
corresponding LIPO spectrum using a regression model. The PERCH
NMR software (Perch Solutions Ltd, Kuopio, Finland) is used for all the
lineshape fitting analyses (Soininen et al, 2005).
Lipoprotein measures and subclass quantification
Lipoprotein profiling by 1H NMR spectroscopy is currently well
established (Ala-Korpela, 1995, 2008) and is incorporated in the serum
NMR metabonomics platform (Soininen et al, 2009). Regarding the
quantifications, we applied here a computationally more efficient
modification of the approach presented recently in Vehtari et al (2007).
Serum concentrations of total TGs and total C, as well as, for example,
VLDL-TG, IDL-C, LDL-C, and HDL-C, were determined. Incorporation
of the NMR measures into the recently introduced computational
approach also enabled estimation of apolipoprotein A-I and APOB
(Niemi et al, 2009). In addition, total lipid and particle concentrations
in 14 lipoprotein subclasseswere obtained, aswell as various subclass-
specific lipid concentrations as total C, in all the LDL subclasses. The
subclasses referred here were calibrated via high-performance liquid
chromatography (Okazaki et al, 2005) and are as follows: chylomi-
crons and extremely large VLDL particles (with particle diameters from
B75nm upwards), five different VLDL subclasses, namely, very large
VLDL (average particle diameter of 64.0 nm), large VLDL (53.6 nm),
mediumVLDL (44.5 nm), small VLDL (36.8 nm), and very small VLDL
(31.3 nm); IDL (28.6 nm), three LDL subclasses as large LDL (25.5 nm),
medium LDL (23.0 nm), and small LDL (18.7); and four HDL
subclasses as very large HDL (14.3 nm), large HDL (12.1 nm), medium
HDL (10.9 nm), and small HDL (8.7 nm).
Immune response marker quantification
Serum concentrations of IgEwere analyzed at the National Institute for
Health and Welfare by Quantia IgE immunoturbidimetric assay
(Biokit, S. A., Barcelona, Spain) using analyzer Architect c8000
(Abbott Laboratories, Abbott Park, IL, USA). The analytical range of
the IgE method was from 25 to 1000 IU/ml. Because nearly half of the
results were below 25 IU/ml, we assumed that there was a linear
correlation between the measured absorbance and the concentration
of IgE. According to the absorbance at 25 IU/ml, we calculated a factor
that we used to generate semiquantitative results for stratifying
samples below 25 IU/ml. The interassay coefficient of variation (CV) of
IgE varied from 2.4% (high level control, 283 IU/ml) to 13% (low level
control, 37 IU/ml).
IL-1ra and HMWA were determined at the National Institute of
Health andWelfare laboratory in Turku. Intra-assay CVs were 5.3, 2.2,
and 2.2% for IL-1ra at nominal concentration levels of 170, 400, and
1485 pg/ml, and 8.5 and 6.3% for HMWA at nominal concentration
levels of 3000 and 6800ng/ml. Interassay CVs were 11.9, 10.3, 9.9, and
9.0% for IL-1ra at nominal concentration levels of 145, 290, 520, and
1290 pg/ml, and 18.1, 18.7, and 19.5% for HMWA at nominal
concentration levels of 3300, 4400, and 9500ng/ml.
Data quality, processing, and normalization
As metabolite distributions did not achieve normality, Box-Cox power
transformations were implemented for each metabolite and the
resulting distributions were corrected for age, gender, and the first 10
principal components by taking the standardized residuals from a
multiple linear regression with the above as covariates. The principal
components are calculated directly from the SNP genotypes and as
such capture genetic variation among the samples. We control for this
variation in the metabolite levels because we wish to remove
metabolite variation which is attributable to genetic population
structure in Finland. Outliers of 44 s.d.s from the mean were
removed. See Supplementary Figure 3 for Spearman’s rank correla-
tions between metabolites.
Processing of the expression data was performed as previously
described (Inouye et al, 2010). Briefly, all arrays were quantile
normalized at the strip-level and technical replicates were combined
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via a bead-count weighted average. Technical replicates were removed
from further analysis if their Pearson’s correlation coefficient was
o0.94 or their Spearman’s rank correlation coefficient was o0.60.
Probes were removed if they mapped to a non-autosomal chromo-
some, erythrocyte globin components, or more than one genomic
position. Genotypes were called and imputed using the Illuminus and
IMPUTE algorithms (Marchini et al, 2007; Teo et al, 2007), respectively,
and underwent stringent filtering for low-quality SNPs, samples,
population structure and relatedness.
Association analysis
All modeling was performed using the R-statistical computing
language (http://www.r-project.org/). After normalization and cor-
rection for confounding variables, each metabolite concentration was
tested for association with the expression values of each gene probe
using linear regression. For each metabolite and gene probe, Yi is the
standardized residual for individual i,Xi is the probe’s log2-normalized
expression value for the individual, and ei is a normally distributed
random variable with mean equal to zero and constant variance:
Yi ¼ aþ bXi þ ei
Nominal P-valueswere calculated for the test of no association, b¼0. A
strict significance level for each metabolite was employed using
Bonferroni’s correction. With 35 419 tests for each metabolite, this
gives a significance level of 1.41106.
Network analysis
Network analysis was carried out using the R-packages, WGCNA
(Langfelder and Horvath, 2008) and NEO (Aten et al, 2008).
WGCNA was used to generate an undirected network model of
genes associated with blood metabolite concentrations. We con-
structed the network using the top 10% of expression signals across all
metabolites (3520 unique probes). Pearson’s correlation coefficients
were used to construct the correlation matrix, and a soft power
threshold of seven (Supplementary Figure 4) was used to generate the
adjacency matrix. The matrix was then hierarchically clustered and a
dynamic tree cut with a minimum module size of 10 probes was used
to identify clusters of tightly correlated genes (i.e., modules or
subnetworks). Individual modules can also be intercorrelated; there-
fore, we used eachmodule’s summary expression profile (first singular
vector) to merge tightly correlated modules at a dendrogram height of
o0.20 (Supplementary Figure 5). Metabolite concentrations were
tested for associationwith eachmodule using the summary expression
profile. A t-test of Spearman’s rank correlation was employed and the
associations presented in heatmaps for each metabolite window
(Supplementary Figures 7–16). In the heatmaps, the LL module
corresponds to module A.
NEO was used to predict the directedness of the network using
causal SNPs as anchors. We only included metabolites that were
associated with LL module expression, not ratios, and, as edge
orienting depends on a sufficient genetic basis for both linked traits,
have at least one SNPassociationwith P-valueo5.0107. This leads
to the inclusion of 29 metabolites in a directed network with core LL
module. For an SNP to be considered as a causal anchor in the network,
it needed to satisfy one of the following: (a) have association P-value
o5.0107 for one or more LL module-associated metabolites, (b) be
in cis to a core LL module gene and have a expression association
P-value o5.0103. To assign SNPs as causal anchors, we adopted
the automatic SNP selection approach implemented in NEO, which
uses both greedy and forward stepwise regression (Aten et al, 2008).
An oriented edge was considered causal according to three criteria: (i)
if its NEO score (in this case the local SEM-based Edge Orienting Next
Best Orthogonal Causal Anchor, LEO.NB.OCA score) was40.30, (ii) if
its causal model P-value was 40.10, and (iii) if its A - B path
coefficient was a Z-score test statistic 41.96 or o1.96. See
Supplementary Table 3 for a full list of network statistics. The
robustness of the SNP selection as causal anchors was evaluated for all
inferred causal edges using the robustness analysis in NEO (Supple-
mentary Figure 17). The combined greedy and forward stepwise
selection approach was used to select the top 1, 2, 3, 4, and 5 most
highly correlated SNPs, as causal anchors for metabolites and
expressed genes, and, for each step, edge-orientation scores were
calculated for the originally inferred edge orientation, i.e., that which
was based on the whole SNP set. This analysis showed that core LL
module’s reactivity to blood metabolites was robust to SNP selection.
Conditional co-expression
It is important to understand how the LL module’s core co-expression
changes with metabolite levels. For each core gene, log2-normalized
expression values were partitioned into quintiles. In order to make
quintile numbers consistent, the last quintile (highest metabolite
concentration) consisted of 0–4 more individuals than other quintiles.
Changing the quintile with 0–4 individuals did not affect downstream
analysis. For each quintile, co-expression was assessed by calculating
Spearman’s rank correlation coefficient between all possible non-
redundant pairs (N¼28) of the LL module core genes. A linear model
was fitted to all co-expression pairs across all quintiles in order to test
the hypothesis that co-expression of module is unaffected by
metabolite concentration, i.e., the fitted linear function has zero slope
(Figure 3). See Supplementary Figure 18 for all metabolites.
Data availability
We have made the metabonomic, transcriptomic, and genomic data
used in this study publically available. Themetabonomicmeasures are
available as Supplementary Table 4, the raw and normalized gene
expression intensities have been deposited in the ArrayExpress
(http://www.ebi.ac.uk/arrayexpress/) under the accession number
E-TABM-1036, and the genotype data has been deposited in the
European Genome-phenome Archive (EGA, http://www.ebi.ac.uk/
ega/) under the accession number EGAS00000000086. Both ArrayEx-
press and EGA are hosted by the European Bioinformatics Institute.
Supplementary information
Supplementary information is available at the Molecular Systems
Biology website (http://www.nature.com/msb).
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